Infliximab administration prior to surgery does not increase surgical site infections in patients with ulcerative colitis

详细信息    查看全文

• 作者：Motoi Uchino (1)
  Hiroki Ikeuchi (1)
  Hiroki Matsuoka (1)
  Toshihiro Bando (1)
  Kaoru Ichiki (2)
  Kazuhiko Nakajima (2)
  Naohiro Tomita (1)
  Yoshio Takesue (2)
  
• 关键词：Ileal ; pouch anal anastomosis ; Infliximab ; Restorative proctocolectomy ; Surgical site infection ; Ulcerative colitis
• 刊名：International Journal of Colorectal Disease
• 出版年：2013
• 出版时间：September 2013
• 年：2013
• 卷：28
• 期：9
• 页码：1295-1306
• 全文大小：174KB
• 参考文献：1. Langholz E, Munkholm P, Davidsen M, Binder V (1992) Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 103:1444-451
  2. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462-476 CrossRef
  3. Yamamoto S, Nakase H, Matsuura M, Honzawa Y, Masuda S, Inui K, Chiba T (2010) Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. J Gastroenterol Hepatol 25:886-91 CrossRef
  4. Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ (2004) Early postoperative complications are not increased in patients with Crohn’s disease treated preoperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 99:878-83 CrossRef
  5. Parsi MA, Achkar JP, Richardson S, Katz J, Hammel JP, Lashner BA, Brzezinski A (2002) Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 123:707-13 CrossRef
  6. Marchal L, D'Haens G, Van Assche G, Vermeire S, Noman M, Ferrante M, Hiele M, Bueno De Mesquita M, D'Hoore A, Penninckx F, Rutgeerts P (2004) The risk of post-operative complications associated with infliximab therapy for Crohn’s disease: a controlled cohort study. Aliment Pharmacol Ther 19:749-54 CrossRef
  7. Selvasekar CR, Cima RR, Larson DW, Dozois EJ, Harrington JR, Harmsen WS, Loftus EV Jr, Sandborn WJ, Wolff BG, Pemberton JH (2007) Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 204:956-62 CrossRef
  8. Mor IJ, Vogel JD, da Luz MA, Shen B, Hammel J, Remzi FH (2008) Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 51:1202-210 CrossRef
  9. Ehteshami-Afshar S, Nikfar S, Rezaie A, Abdollahi M (2011) A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease. Arch Med Sci 6:1000-012 CrossRef
  10. Yang Z, Wu Q, Wu K, Fan D (2010) Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther 31:486-92 CrossRef
  11. Uchino M, Ikeuchi H, Matsuoka H, Tsuchida T, Tomita N, Takesue Y (2010) Risk factors associated with surgical site infection after ileal pouch-anal anastomosis in ulcerative colitis. Dis Colon Rectum 53:143-49 CrossRef
  12. Cornillie F, Shealy D, D'Haens G, Geboes K, Van Assche G, Ceuppens J, Wagner C, Schaible T, Plevy SE, Targan SR, Rutgeerts P (2001) Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 15:463-73 CrossRef
  13. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG (1992) CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol 13:606-08 CrossRef
  14. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1988) CDC definitions for nosocomial infections. Am J Infect Control 16:128-40 CrossRef
  15. Truelove SC, Witts LJ (1955) Cortison in ulcerative colitis. Final report on a therapeutic trial. Br Med J 2:1041-045 CrossRef
  16. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1988) CDC definitions for nosocomial infections. Am J Infect Control 16:128-40 CrossRef
  17. Horan TC, Andrus M, Dudeck MA (2008) CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36:309-32 CrossRef
  18. Sandborn WJ, Loftus EV (2004) Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut 53:780-82 CrossRef
  19. Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ (2004) Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 99:878-83 CrossRef
  20. den Broeder AA, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, de Waal-Malefijt M, van den Hoogen FH (2007) Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 34:689-95
  21. Selvasekar CR, Cima RR, Larson DW, Dozois EJ, Harrington JR, Harmsen WS, Loftus EV Jr, Sandborn WJ, Wolff BG, Pemberton JH (2007) Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 204:956-62 CrossRef
  22. Mor IJ, Vogel JD, da Luz MA, Shen B, Hammel J, Remzi FH (2008) Infliximab in ulcerative colitis is associated with an increasing risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 51:1201-210 CrossRef
  23. Ehteshami-Afshar S, Nikfar S, Rezaie A, Abdollahi M (2011) A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease. Arch Med Sci 6:1000-012 CrossRef
  24. Cornillie F, Shealy D, D'Haens G, Geboes K, Van Assche G, Ceuppens J, Wagner C, Schaible T, Plevy SE, Targan SR, Rutgeerts P (2001) Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 15:463-73 CrossRef
  25. Lim M, Sagar P, Abdulgader A, Thekkinkattil D, Burke D (2007) The impact of preoperative immunomodulation on pouch-related septic complications after ileal pouch-anal anastomosis. Dis Colon Rectum 50:943-51 CrossRef
  26. Ahn HS, Lee SK, Kim HJ, Jang JY, Joo KR, Dong SH, Kim BH, Lee JI, Chang YW, Chang R (2006) Risk of postoperative infection in patients with inflammatory bowel disease. Korean J Gastroenterol 48:306-12
  27. Miki C, Ohmori Y, Yoshiyama S, Toiyama Y, Araki T, Uchida K, Kusunoki M (2007) Factors predicting postoperative infectious complications and early induction of inflammatory mediators in ulcerative colitis patients. World J Surg 31:522-29 CrossRef
  28. Subramanian V, Pollok RC, Kang JY, Kumar D (2006) Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br J Surg 93:793-99 CrossRef
  29. Petrosillo N, Drapeau CM, Nicastri E, Martini L, Ippolito G, Moro ML et al (2008) Surgical site infections in Italian hospitals: a prospective multicenter study. BMC Infect Dis 8:34 CrossRef
  30. Edwards JP, Ho AL, Tee MC, Dixon E, Ball CG (2012) Wound protectors reduce surgical site infection: a meta-analysis of randomized controlled trials. Ann Surg 256:53-9 CrossRef
  
• 作者单位：Motoi Uchino (1)
  Hiroki Ikeuchi (1)
  Hiroki Matsuoka (1)
  Toshihiro Bando (1)
  Kaoru Ichiki (2)
  Kazuhiko Nakajima (2)
  Naohiro Tomita (1)
  Yoshio Takesue (2)
  
  1. Department of Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan
  2. Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
  

文摘

Purpose The high incidence of infectious complications in ulcerative colitis (UC) is generally recognized to be due to several factors related to a compromised host. In our previous study, a high dose of corticosteroid was shown to be a risk factor for surgical site infection (SSI). Recently, infliximab (IFX) has been used for refractory UC. In this study, the effect of IFX on the occurrence of infectious postoperative complications for UC was evaluated, because it remains controversial. Method A total of 196 UC patients who underwent laparotomy between January 2010 and September 2012 were included. Possible factors related to complications were analyzed to identify significant predictors. Results Twenty-two patients had IFX before surgery. The overall incidence of SSI was 47/196 (24.0?%). The incidence of infections, including SSI and other infections, was 69/196 (35.2?%). On multivariate analysis, national nosocomial infection surveillance (NNIS) risk index ? (p<0.01) and preoperative prednisolone dose ?.2 mg/kg/day (p--.01) were identified as independent risk factors for overall SSI; NNIS risk index ? (p <0.01) and duration from onset of UC ?.3?years (p--.045) were identified as independent risk factors for incisional SSI; contaminated wound class (p <0.01), preoperative hospital stay ??days (p--.048), severe/fulminant disease activity (p--.04), and pancolitis (p--.02) were identified as independent risk factors for organ/space SSI; and contaminated wound (p-lt;-.01), severe/fulminant disease activity (p--.02), and age at surgery ?3?years (p--.047) were identified as independent risk factors for total infectious complications. Conclusion IFX administration was not associated with infectious complications for UC surgery.